EWALL-PH OBSERVARTORY 2022
ConditionAcute Lymphoblastic Leukemia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorVersailles Hospital
About this trial
An observatory for patients aged 18 years and over with Philadelphia chromosome positive (Ph+ or BCR::ABL1) acute lymphoblastic leukemia (ALL) and treated with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticosteroids and/or a monoclonal antibody.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male or female patients ≥ 18 years
Philadelphia chromosome or BCR::ABL1 positive acute lymphoblastic leukaemia
Treatment with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticotherapy and/or a monoclonal antibody
Disqualifiers
Patients deceded and having previously refused data collection
Not included in a prospective clinical trial
Trial population
Acute Lmphoblastic Leukaemia with Philadelphia chromosome or BCR::ABL1 positive
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Overall survival by 12 months
Time frame
12 monthsSecondary outcomes
1
overal survival by 36 months
Time frame
36 months2
proportion of complete remission
Time frame
36 months3
the molecular response defined by BCR//ABL1/ABL1 ratio in bone marrow and/or peripheral blood
Time frame
36 months4
the molecular response defined by IGTR quantification proportion in bone marrow and/or peripheral blood
Time frame
36 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov